Angiogenic molecules and cancer metastasis

In Vivo

Volumn 12, Issue 1, 1998, Pages 27-34

  Kumar, Rakesh ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Host microenvironment; Metastasis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; TUMOR CELL; TUMOR VASCULARIZATION;

EID: 0031955521     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res 50: 6130-6138, 1990.
2. Sugarbaker EV: Cancer metastasis: a product of tumor-host interactions, Curr Probl Cancer 3: 1-59, 1979.
3. Weiss L: Principles of metastasis. Orlando, Academic Press, 1985.
4. Fidler IJ: Experimental orthotopic models of organ-specific metastasis by human neoplasms. Adv Mol Cell Biol 9: 191-215, 1994.
5. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87: 1588-1592, 1995.
6. Folkman J: The role of angiogenesis in tumor growths. Semin Cancer Biol 3: 65-71, 1992.
7. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1: 27-31, 1995.
8. Folkman J: Clinical applications of research on angiogenesis. N Eng J Med 333: 1753-1763, 1995.
9. Auerbach W and Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 63: 265-311, 1994.
10. Dvorak HF: Tumors; wounds that do not heal. N Eng J Cancer 315: 1650-1659, 1986.
11. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054s-5059s, 1991.
12. Gasic GJ: Role of plasma, platelets and endothelial cells in tumor metastasis. Cancer Metastasis Rev 3: 99-105, 1984.
13. Fidler IJ and Bucana C: Mechanism of tumor cell resistance to lysis by syngenic lymphocytes. Cancer Res 37: 3945-3956, 1977.
14. Weiss L: Biochemical interactions of cancer cells with the microvasculature during hematogenous metastasis. Cancer Metastasis Rev 11: 227-235, 1992.
15. Nicolson GL: Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948: 175-208, 1988.
16. Zetter BR: The cellular basis of site-specific tumor metastasis. N Eng J Med 522: 605-612, 1990.
17. Hart IR and Saini A: Biology of tumor metastases. Lancet 339: 1437-1453, 1992.
18. Radinsky R: Paracrine growth regulation of human colon carcinoma organ- specific metastasis. Cancer Metastasis Rev 12: 345-361, 1993.
19. Folkman J: Endothelial cells and angiogenic growth factors in cancer growth and metastasis (Introduction). Cancer Metastasis Rev 9: 171-174, 1990.
20. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
21. Fidler IJ, Gersten DM and Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 25: 149-250, 1978.
22. Fidler IJ: Metastasis: Quantitative analysis of distribution and fate of tumor cells emboli labeled with '2sl-5-iodo-deoxyuridine. J Natl Cancer Inst 45: 773-782, 1970.
23. Fidler IJ and Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895, 1977.
24. Poste G and Fidler IJ: The pathogenesis of cancer metastasis. Nature 253: 139-146, 1980.
25. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1889.
26. Fidler IJ and Hart IR: Biological diversity in metastatic neoplasms: origin and implications. Science 217: 998-1003, 1982.
27. Price JE, Aukerman SL and Fidler IJ: Evidence that the process of murine melanoma metastasis is sequential and selective and contain stochastic elements. Cancer Res 46: 5172-5178, 1986.
28. Talmadge JE, Wolman SR and Fidler IJ: Evidence for the clonal origin of spontaneous metastasis. Science 217: 361-363, 1982.
29. Fidler IJ and Talmadge JE: Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 46: 5167-5171, 1986.
30. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gaspanni G: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
31. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
32. Weidner N and Folkman J: Tumoral vascularity as a prognostic factor in cancer. In: Important advances in Oncology (DeVita VT, Hellman S, and Rosenberg SA eds). Philadelphia, Lippincott-Raven Publishers, 1996, pp167-190.
33. Fidler IJ and Ellis LM: The implication of angiogenesis to the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
34. Ellis LM and Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 324: 2451-2460, 1996.
35. Liotta LA, Kleinerman J and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1003, 1974.
36. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
37. Bouck N, Stellmach V and Hsu SC: How tumors become angiogenic. Adv Cancer Res 69: 135-174, 1996.
38. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
39. Cockerill GW, Gamble JR and Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol 159: 113-160, 1995.
40. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R and Klagsbrun M: Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J Biol Chem 29: 275-287, 1985.
41. Leung ZW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
42. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM and Feder J: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470-1478, 1989.
43. Plate KH, Breier G, Weich HA and Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
44. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
45. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner NM, Elner SG and Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801, 1992.
46. Ishikawa F, Miyazone K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin C-H: Induction of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557-562, 1989.
47. Heldin C-H: Structural and functional studies on platelet-derived growth factor. EMBO J 11: 4251-4259, 1992.
48. Bussolino F, DiRenzo MF, Ziche M, Bocchietto M, Olivero M, Naldini L, Gaudino G, Tamagone L, Coffer A and Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641, 1992.
49. Rosen EM, Grant DS, Kleinman HK, Goldberg ID, Bhargara MM, Nichollof EJ, Kinsella JL and Polverini P: Scatter factor (hepatocyte growth factor) is a potent angiogenic factor in vivo. Symp Soc Exp Biol 47: 227-234, 1993.
50. Dameron KM, Volpert OV, Tanisky MA and Bouk N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1502-1504, 1994.
51. Hanahan D, Christofori G, Naik P and Arbeit J: Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 32A: 2386-2393, 1996.
52. Singh RK, Llansa N, Bucana CD, Sanchez R, Koura A and Fidler IJ: Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells. Cell growth Differentiation 7: 397-404, 1996.
53. Koura AN, Liu W, Kitadai Y, Radinsky R and Ellis LM: Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by cell density. Cancer Res 56: 3891-3894, 1996.
54. Kitadai Y, Ellis LM, Takahashi Y, Bucana CD, Anzai H, Tahara T, and Fidler IJ: Multiparametric in situ mRNA hybridization analysis to detect metastasis- related genes in surgical specimens of human colon carcinoma. Clin Cancer Res 1: 1095-1102, 1995.
55. Kitadai Y, Ellis LM, Tucker SL, Greene GF, Bucana CD, Cleary KR, Takahashi Y, Tahara E and Fidler IJ: Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 149: 1541-1551, 1996.
56. Ezekowitz RAB, Mulliken JB and Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Eng J Med 326: 1456-1463, 1992.
57. Ricketts RR, Hatley RM, Corden BJ, Sabio H and Howell CG: Interferon alpha-2a for the treatment of complex hemangiomas of infancy and childhood. Ann Surg 6: 605-614, 1994.
58. Ohlms LA, Jones DT, McGill TJ and Healy GB: Interferon-alpha-2A therapy for airway hemangiomas. Ann Otol Rhinol Laryngol 103: 1-8, 1994.
59. Orchard PJ, Smith CM, Woods WG, Day DL, Debner Lp and Shapiro R: Treatment of hemangioendotheliomas with alpha interferon. Lancet 2: 565-567, 1989.
60. White CW, Sondheimer HM, Crouch EC, Wilson H and Fan LL: Treatment of pulmonary hemangiomatosis with recombinant interfern-alpha-2a. N Eng J Med 520: 1197-1200, 1989.
61. Soumekh B, Adams GL and Shapiro RS: Treatment of head and neck hemangiomas with recombinant interferon-alpha-2b. Ann Otol Rhinol Laryngol 105: 201-206, 1996.
62. Kirn DH and Kramer A: Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 88: 764-765, 1996.
63. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derzin M, Weinstein WM, Casavante C, et al: Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100: 671-676, 1984.
64. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N and Fidler IJ: Interferon α and ß down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92: 4562-4566, 1995.
65. Singh RK, Gutman M, Radinsky R, Bucana CD and Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 54: 3242-3247, 1994.
66. Gutman M, Singh RK, Xie K, Bucana CD and Fidler IJ: Regulation of interleukin-8 expression in human melanoma cells by the organ environment. Cancer Res 55: 2470-2475, 1995.
67. Singh RK, Gutman M, Llansa N and Fidler IJ: Interferon-ß prevents the upregulation of interleukin-8 expression in human melanoma cells. J Interferon Cytokine Res 16: 577-584, 1996.
68. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993.
69. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF and Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in kidney and bladder carcinomas. Am J Pathol 143: 1255-1262, 1993.
70. Shweiki D, Itin A, Stoffer D and Keshet E; Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 559: 843-845, 1992.
71. Ikeda E, Achen MG, Breier G and Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 34: 19761-19768, 1995.
72. Levy AP, Levy NS, Wegner S and Goldberg MA: Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333-13340, 1995.
73. Koochekpour S, Merzak A and Filkington GJ: Vascular endothelial growth factor production is stimulated in response to growth factors in human glioma cells. Oncology Reports 2: 1059-1061, 1995.
74. Tsai JC, Goldman CK and Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 358: 311-315, 1995.
75. Cohen T, Nahari D, Cerem LW, Neufeld G and Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 277: 736-741, 1996.
76. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, Patterson C, Endego WO, Zhou F and Lee ME: Induction of vascular endothelial growth factor gene expression by interleukin-1b in rat aortic smooth muscle cells. J Biol Chem 270: 308-312, 1995.
77. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O and Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-ß in fibrofalastic and epithelial cells. J Biol Chem 269: 6271-6274, 1994.
78. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
79. Rak J. Filmus J, Finkenzeller G, Grugel S, Marme D and Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Met Rev 74: 263-277, 1995.
80. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS and Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-src activation. Nature 375: 577-581, 1995.
81. Mukhopadhyay D, Tsiokas L and Sukhatme VP: Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
82. Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AP and Reuter VE: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85: 1597-1599, 1993.
83. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986.
84. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR and Fidler IJ: Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 145: 365-374, 1994.
85. Takahashi Y, Mai M, Wilson MR, Kitadai Y, Bucana CD and Ellis LM: Site-dependent expression of vascular endothelial growth factor, angiogenesis and proliferation in human gastric carcinoma. Int J Oncol 8: 701-705, 1996.
86. Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR and Ellis LM: Platelet derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl cancer Inst 88: 1146-1151, 1996.
87. Sidky YA and Auerbach R: Lymphocyte-induced angiogenesis in tumor- bearing mice. Science 192: 1237-1238, 1976.
88. Meininger CJ and Zetter BR: Mast cells and angiogenesis. Semin Cancer Biol 3: 73-79, 1992.
89. Fidler IJ: Lymphocytes are not only immunocytes (guest editorial). Biomedicine 32: 1-3, 1980.
90. Fidler IJ, Gersten DM and Kripke ML: Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 39: 3816-3821, 1979.
91. Miguez M, Davel L and deLustig ES: Lymphocyte-induced angiogenesis: correlation with the metastatic incidence of two murine mammary adenocarcinomas. Invasion Metastasis 6: 313-320, 1986.
92. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE and Klagsbrun M: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140-4145, 1995.
93. Polverini P, Cotran R, Gimbrone N and Unanue E: Activated macrophages induce vascular proliferation. Nature 269: 804-805, 1977.
94. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R and Sorg C: Macrophages and angiogenesis. J Leukocyte Biol 55: 410-422, 1994.
95. Leek RD, Harris AL and Lewis CE: Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukocyte Biol 56: 423-435, 1994.
96. Srivastava A, Laidler P, Davies RP, Horgan K and Hughes LE: The prognostic significance of tumor vascularity in intermediate thickness (0.76- 4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 133: 419-423, 1988.
97. Ruiter DJ, Bhan AK, Harris TJ, Sober AJ and Mihm Jr MC: Major histocompatibilty antigens and the mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 129: 2808-2815, 1982.
98. Brocker EG, Rechenbeld C, Hamm H, Ruiter DJ and Sorg C: Macrophages in melanocytic naevi. Arch Dermatol Res 284: 127-131, 1992.
99. Kreisle RA, Stebler BA and Ershler WB: Effect of host age on tumor-associated angiogenesis in mice. J Natl Cancer Inst 82: 44-47, 1990.
100. Ding A, Hwang S and Schwab R: Effect of aging on murine macrophages: diminished response to IFN-γ for enhanced oxidative metabolism. J Immunol 153: 2146-2152, 1994.
101. Goidl E: ed. Aging and the immune response: cellular and humoral aspects. New York: Marcel Dekker, 1987.
102. Weksler ME and Schwab R: The immunogenetics of immune senescence. Exp Clin Immunogenet 199: 182-187, 1992.
103. DiPietro LA and Polverini PJ: Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 143: 678-684, 1993.
104. Rappolee DA, Mark D, Banda MJ and Werb Z: Wound macrophages express TGF-α and other growth factors in vivo analysis by mRNA phenotyping. Science 241: 708-712, 1988.
105. Fumagalli U, Trabucchi E, Soligo M, Rosati R, Rebuffat C, Tonelli C and Montorsi M: Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Sur Res 50: 82-87, 1991.
106. Noh R, Karp GI and Devereaux DF: The effect of doxorubicin and mitoxanthrone on wound healing. Cancer Chemother Pharmacol 29: 141-144, 1991.
107. Gutman M, Singh RK, Yoon S, Xie K, Bucana CD and Fidler IJ: Leukocyte- induced angiogenesis and subcutaneous growth of B16 melanoma. Cancer Biother 9: 163-170, 1994.
108. Polverini JJ and Leibovich SJ: Induction of neovascularization in vivo and endothelial cell proliferation in vitro by tumor-associated macrophages. Lab Invest 51: 635-642, 1984.
109. Sunderkotter C, Goebeler M, Schultze-Osthoff K, Bhardwaj R and Sorg C: Macrophage-derived angiogenic factors. Pharmacol Ther 51: 195-216, 1991.
110. Polverini PJ: How the extracellular matrix and macrochaaes contribute to angiogenesis-dependent diseases. Eur J Cancer 32A: 2430-2437, 1996.
111. Ingber D: Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 47: 236-241, 1991.
112. Ingber DE and Folkman J: How does extracellular matrix control capillary morphogenesis. Cell 58: 803-805, 1989.
113. Lingen MW, Polverini PJ and Bouck N: Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest 74: 476-483, 1996.
114. Lingen MW, Polverini PJ and Bouck N: Retinoic acid induces cells cultured from oral squamous cell carcinomas to become antiangiogenic. Am J Pathol 149: 247-258, 1996.
115. Dong Z, Kumar R, Yang X and Fidler IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 83: 801-810, 1997.
116. Kumar R, Dong Z and Fidler IJ: Differential regulation of metalloelastase activity in murine peritoneal macrophages by GM-CSF and M-CSF. J Immunol 157: 5104-5111, 1996.
117. Fidler IJ and Poste G: The cellular heterogeneity of malignant neoplasms: implications for adjuvant chemotherapy. Semin Oncol 12: 207-221, 1985.